1. Bertilsson L, Eichelbaum M, Mellström B, Säwe J, Schulz H-U, Sjöqvist F (1980) Nortrip-tyline and antipyrine clearance in relation to the debrisoquine hydroxylation in man. Life Sci
27: 1673–1677
2. Boobis AR, Murray S, Kahn GC, Robertz G-M, Davies DS (1983) Substrate specificity of the form of cytochrome P-450 catalysing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol
23: 474–481
3. Boobis A, Edwards RJ, Singleton A, Sesardic D, Murray B, Speirs CJ, Murray S, et al. (1988) The contribution of polymorphic isozymes of cytochrome P-450 to the pharmacokinetics and toxicity of foreign compounds in man. In: Miners J, Birkett DJ, Drew R, McManus M (eds) Microsomes and drug oxidation. Taylor and Francis, London, pp 216–223
4. Brinn R, Br0sen K, Gram LF, Haghfelt T, Otton SY (1986) Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol
22: 194–197
5. Brøsen K, Gram LF, (1989) Quinidine potently inhibits the 2-hydroxylation of imipramine and desipramine, but not the demethylation of imipramine. Eur J Clin Pharmacol (in press)